About Simtra BioPharma Solutions

As the premier, independently owned Contract Development Manufacturing Organization with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions offers world-class cGMP sterile fill and finish, technical expertise, quality service, and a uniquely collaborative approach to support its customers' strategic objectives. Biotech and pharmaceutical companies partner with Simtra when they need to take their molecule to market, whether launching an innovation globally, improving a formulation, or proactively mitigating risk to grow their business. Simtra's teams of tenured experts deliver tailored, flexible solutions to help customers consistently fulfill their product goals at the highest quality, so they get in the hands of the patients who need them most.

Here you will find Simtra BioPharma Solutions

Last viewed contents

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

European Medicines Agency recommends that Linoladiol N and Linoladiol HN remain available - Benefits continue to outweigh risks with new restrictions

Advises on compassionate use of a new combination therapy for chronic hepatitis C - Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease

EMA recommends approval of new treatment for platinum-resistant ovarian cancer - Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond

EMA endorses revised policy on handling of declarations of interests

Recommendation against combined use of medicines affecting the renin-angiotensin system

UK Agency’s Update on “Three-Person IVF” Leaves Safety Questions Unresolved - Parliamentary Vote Would be Premature, Says Public Interest Group

EMA to relocate to Amsterdam - Working with Dutch government to ensure successful move by end of March 2019

BIO Urges EPA to Fully Consider Impacts of Renewable Fuel Standard Waiver Requests

From Promise to Productivity: Smart Policy for Sustainable EU Growth Through Biobased Products and Industrial Biotechnology

Genetically Modified Humans? Seven Reasons to Say “No”

New Standards in Biotechnology